YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

More Trouble for GSK in China

July 25, 2013 | The New York Times has unearthed more trouble for GlaxoSmithKline in China. In addition to bribery allegations in terms of drug sales, the newly revealed documents suggest corruption in research as well as GSK's Shanghai R&D center. New York Times
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.